They definitely need more funds, but I like they way they are handling the financing. Paying off notes with new funding and if you look at the rounds of financing since June 30, they were all done at 0.008, not convertible notes. O/S is still right where we knew it would be. There has been a lot of steady buying in the last month and I believe we move up significantly from here. They have a great plan to finance adva trials with generic drug funds (as well as some financing, I assume). Market cap here is still extremely low and this could be swallowed up for 20-30x in a heartbeat by a pharma. All IMO
News 
Market Data 
Discover 
